Fig 1.
Rate (%) of antimicrobial susceptibility to 11 antipseudomonal antimicrobial agents of extensively drug-resistant Pseudomonas aeruginosa (XDR-PA), multidrug resistant P. aeruginosa (MDR-PA), and non-MDR PA.
AK: amikacin; CAZ: ceftazidime; CEF: cefepime; CFX: ciprofloxacin; COL: colistin; DOR: doripenem; GM: gentamicin; IMP: imipenem; MER: meropenem; NET: netilmicin; TZP: Piperacillin/tazobactam.
Table 1.
Demographics and clinical characteristics of patients with extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) and non-XDR-PA infection.
Table 2.
Treatment, and clinical and microbiological outcomes, of patients with Pseudomonas aeruginosa infections.
Table 3.
Independent predictors of XDR-PA infections.
Table 4.
Independent predictors of mortality attributable to infection.